CyTuVax Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 2

CyTuVax General Information

Description

Provider of a vaccination platform technology intended to protect against viral and bacterial pathogens. The company's technology is based on depot-attached cytokines as an immune stimulator that induces immune responses, both humoral and cellular, and can be applied in prophylactic and therapeutic vaccine concepts, enabling patients to get treated against diseases and generate immune responses.

Contact Information

Website
www.cytuvax.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Oxfordlaan 55
  • 6229 EV Maastricht
  • Netherlands
+31 043 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CyTuVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 00.000 Completed Clinical Trials - Phase 3
3. Grant 23-Oct-2018 000.00 00.000 Completed Clinical Trials - Phase 3
2. Early Stage VC 30-Oct-2015 $291K $1.85M Completed Generating Revenue
1. Seed Round 25-Oct-2012 $1.56M $1.56M Completed Startup
To view CyTuVax’s complete valuation and funding history, request access »

CyTuVax Executive Team (3)

Name Title Board Seat Contact Info
René Vleugels Ph.D Co-Founder & Chief Executive Officer
Frank Falkenberg Co-Founder & Scientific Director
Paul Brekel Commercial & Financial Officer
To view CyTuVax’s complete executive team members history, request access »

CyTuVax Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Horizon 2020 Government 000 0000 000000 0
Limburg Business Development Fund Venture Capital Minority 000 0000 000000 0
To view CyTuVax’s complete investors history, request access »